GleamWall
中文EN

BDPT BIOADAPTIVES, INC.

Pharmaceutical Preparations · OTC · SEC CIK 1575142 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY230.2%
TTM net income YoY-106.3%
TTM EPS YoY—
Revenue 3-yr CAGR0.7%
Net income 3-yr CAGR—

Margins

Gross margin77.0%
Operating margin-3,610.9%
Net margin-8,805.9%
FCF margin—
EBITDA margin-3,587.7%

Returns

ROE—
ROA-2,510.3%
ROIC (approx.)—
Asset turnover0.29x

Leverage & solvency

Liabilities / assets4,703.4%
Debt / equity—
Current ratio0.02x
Interest coverage-2.42x

Cash quality & payout

Operating cash flow / net income0.17x
Accruals ratio-2,071.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$18,278$12,669
Cost of revenue$5,781$8,639
Gross profit$12,497$4,030
SG&A expense$820,508$335,306
Operating income-$1.04M-$602,090
Interest expense$70,880$91,978
Pretax income-$1.56M-$899,161
Income tax$0$0
Net income-$1.56M-$899,161
EBITDA-$1.04M-$602,090
EPS (basic)—-0.11
EPS (diluted)-0.15-0.11
Weighted avg. shares (diluted)10.07M8.22M
Balance sheet
Cash & equivalents$158,445$137,470
Short-term investments$0$0
Inventory$44,706$19,115
Current assets$211,901$261,885
PP&E, net$14,000$0
Intangibles$14,000$0
Total assets$225,901$261,885
Current liabilities$2.36M$1.73M
Total liabilities$2.36M$1.73M
Shareholders' equity-$2.13M-$1.46M
Shares outstanding12.01M8.22M
Cash flow statement
Operating cash flow-$516,025-$249,517
Capital expenditure$18,000$0
Free cash flow-$534,025-$249,517
Investing cash flow-$18,000$0
Financing cash flow$555,000$326,211
Depreciation & amortization$4,000$0
Stock-based compensation$28,670—

Free plan shows the latest 2 periods; Pro shows all 10 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.